NBIX compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

NBIXNeurocrine Biosciences Inc

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

NBIXNeurocrine Biosciences Inc

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NBIX

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±9.3%▲+13.42%×1.44

Q2 FY26—▼−10.08%—

Q1 FY26—▲+8.86%—

Feb 12 '26—▼−10.43%—

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedNBIX realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 14%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

NBIXNeurocrine Biosciences Inc

164.56▲+3.01%· post 164.56

Mkt cap$16.7BRevenue$1.1BQ3 FY26Revenue$2.9BFY25

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

NBIXNeurocrine Biosciences Inc

AMGNAmgen Inc

164.56▲+3.01%post 164.56

Price

460.55▲+0.06%post 460.42

$16.7B

Mkt cap

$249.0B

Q3 FY26$1.1B

Revenue

$10.4BQ3 FY26

FY25$2.9B

Revenue

$36.8BFY25

NBIX164.56▲+3.01%vsAMGN460.55▲+0.06%ClosedNov 6 '26